NCT05587361 Beta-Adrenergic Modulation of Drug Cue Reactivity
| NCT ID | NCT05587361 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Oklahoma |
| Condition | Tobacco Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-11-26 |
| Primary Completion | 2027-03-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
Eligibility Criteria
Inclusion Criteria: 1. Generally healthy 2. Age 21-60 3. Right-handed using a three-item scale 4. Daily smoker of ≥ 5 cigarettes/day delivering 0.5 mg nicotine (FTC) 5. Smoking regularly for ≥ 1 year, with stable smoking for the past 6 months 6. Afternoon expired Carbon Monoxide (CO) concentration ≥ 6 ppm and/or morning urinary cotinine \>100 ng/ml 7. Must identity at least 4 different smoking locations used in a typical week 8. Able to read and understand English Exclusion Criteria: 1. Inability to attend all required sessions 2. Significant health problems that would preclude active participation 3. Presence of conditions that would make MRI unsafe (e.g. pacemaker) or (e.g. weight and body shape) 4. Current use of psychoactive medications/drugs as indicated by self-report or urine screen 5. Positive breath alcohol concentration 6. Pregnant, breastfeeding, or planning to become pregnant during the course of the study (females) 7. Problems with vision that cannot be corrected with cont